AI assistant
Sending…
Forte Biosciences, Inc. — Director's Dealing 2017
Apr 12, 2017
33769_dirs_2017-04-12_1b924b00-4d00-4456-af84-12564283bb4c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-04-12
Reporting Person: DARCY THOMAS E (Director, Executive Vice President)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 369565 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $3.94 | 2023-03-13 | Common Stock (66666) | Direct | |
| Employee Stock Option (right to buy) | $14.98 | 2026-06-09 | Common Stock (16666) | Direct |
Footnotes
F1: The stock option is fully vested.
F2: 1/4th of the shares vest one year after 4/1/2016; 1/48th of the shares vest monthly thereafter over the next 3 years.
More from Forte Biosciences, Inc.
Regulatory Filings
2026
Jun 2
Share Issue/Capital Change
2026
Jun 2
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 2
Earnings Release
2026
May 14
Capital/Financing Update
2026
Apr 9
Capital/Financing Update
2026
Apr 9
Capital/Financing Update
2026
Apr 8
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Jan 29
Major Shareholding Notification
2026
Jan 20